^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FAM13C (Family With Sequence Similarity 13 Member C)

    i
    Other names: Family With Sequence Similarity 13 Member C, Protein FAM13C, Family With Sequence Similarity 13, Member C1, FAM13C1, Family With Sequence Similarity 13, Member C, FAM13C
    Associations

    News

    Trials
    almost2years
    Transcriptomic and proteomic study of cancer cell lines exposed to actinomycin D and nutlin-3a reveals numerous, novel candidates for p53-regulated genes. (PubMed, Chem Biol Interact)
    In this study, using mass spectrometry and Western blotting, we detected expression of DRAXIN in a medium of A549 cells exposed to A + N. Thus, this protein functions not only in the development of the nervous system, but it may also have a new cancer-related function.
    Preclinical • Journal
    |
    TNFRSF14 (TNF Receptor Superfamily Member 14) • ICOSLG (Inducible T Cell Costimulator Ligand) • MAFB (MAF BZIP Transcription Factor B) • CDH3 (Cadherin 3) • FAM13C (Family With Sequence Similarity 13 Member C)
    |
    dactinomycin • Nutlin-3
    over2years
    FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC. (PubMed, Front Mol Biosci)
    This study successfully developed and validated novel biomarkers based on FFGs for predicting the prognosis and immune status of UCEC patients. The identified FFGs can accurately assess the prognosis of UCEC patients and facilitate the identification of specific subgroups of patients who may benefit from personalized treatment with immunotherapy and chemotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • FAM13C (Family With Sequence Similarity 13 Member C) • FAM72A (Family With Sequence Similarity 72 Member A)
    over4years
    Case Study of Noni Extract in Men with Very Low-Risk or Low-Risk Prostate Cancer. (PubMed, Hawaii J Health Soc Welf)
    Changes were observed in the expression levels of several genes, including FAM13C, KLK2 (associated with the androgen pathway), and GSTM2 (associated with cellular organization) at 12 months. Noni supplementation was associated with favorable clinical parameters, including stable serum PSA among most patients and no evidence of tumor on repeat biopsy, and correlated with modulation of numerous genes and proteins.
    Journal • Clinical
    |
    KLK2 (Kallikrein-related peptidase 2) • FAM13C (Family With Sequence Similarity 13 Member C)
    |
    Oncotype DX Genomic Prostate Score® Assay